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Abstract
Mutations in the CACNA1A gene are associated with episodic ataxia type 2 (EA2) and spinocerebellar
ataxia type 6 (SCA6). CACNA1A encodes the a-subunit of the P/Q-type calcium channel or CaV2.1,
which is highly enriched in the cerebellum. It is one of the main channels linked to synaptic
transmission throughout the human central nervous system. Here, we compare recent advances in
the understanding of the genetic changes that underlie EA2 and SCA6 and what these new findings
suggest about the mechanism of the disease.
Introduction and context
The CaV2.1 calcium channel belongs to the superfamily
of voltage-gated calcium channels. Its other designation,
P/Q-type channel, refers to the cell types from which its
constituentcurrentswereoriginallyisolated;the‘P’stands
for Purkinje and ‘Q’ for granule cells of the cerebellum.
The a-subunit (Figure 1), encoded by CACNA1A,i sa s s o -
ciated with b and a2d auxiliary subunits that are thought to
help in trafficking and anchoring the principal subunit to
the cell membrane and also modulate the biophysical
properties of the channel [1]. CACNA1A undergoes exten-
sive alternative splicing resulting in CaV2.1 channels with
different properties [2-5]. These splice variants are differen-
tially expressed throughout the central nervous system
(CNS)andservetoadjustthebiophysicalparametersofthe
channel to its role in the various cell types.
The CACNA1A gene maps to chromosome 19p13 [6]. It is
widelyexpressedthroughouttheCNS;however,inkeeping
with its original identification, this gene is expressed at a
particularly high level in Purkinje and granule cells of the
cerebellum. In much of the CNS, CaV2.1 channels are
highly expressed pre-synaptically [7], where they couple
calcium influx to vesicular exocytosis in fast neurotrans-
mission. However, in Purkinje cells, CaV2.1 channels serve
an additional post-synaptic role in coordinating AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
receptor activation with voltage-dependent calcium
influx [8].
CaV2.1 and ataxia
Dominant mutations in CACNA1A underlie at least three
allelic diseases (Table 1). A large number of different
point mutations (both nonsense and missense) have
been shown to cause episodic ataxia type 2 (EA2), an
acetazolamide-responsive disorder characterised by par-
oxysmal attacks of midline cerebellar disturbance man-
ifesting as ataxia, imbalance, vomiting, oscillopsia, and
interictal nystagmus [9-15]. Attacks last from hours to
days, and triggers include stress and intercurrent infec-
tion. Several other EA syndromes have been described
(reviewed in [16]); mutations in KCNA1 – the gene that
encodes the KV1.1 potassium channel – underlie EA1,
which is characterised by brief attacks of ataxia (lasting
minutes) with interictal myokymia [17-20]. Interest-
ingly, mutations in CACNB4, the gene that encodes one
of the accessory b-subunits of CaV2.1, also cause a form
of EA [21].
EA2 mutations that result in premature stop codons are
likely to generate a non-functional truncated peptide or
trigger nonsense-mediated mRNA decay. Functional
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demonstrated that mutations associated with EA2 result
in a loss of CaV2.1 channel function [22,23]. In addition,
mutant subunits may disrupt the membrane trafficking
of wild-type channels [24].
In contrast to EA2, spinocerebellar ataxia type 6 (SCA6)
is a ‘pure’ progressive cerebellar syndrome that results,
not from point mutations, but from an abnormal
polyglutamine expansion in the channel’s carboxyl-
terminal domain, which is present in only certain splice
isoforms of the CACNA1A mRNA [25]. Although
changes in channel kinetics have been observed
[26,27], the pathogenic mechanism of SCA6 is poorly
understood.
Recent advances
Direct sequencing of CACNA1A in a number of patients
with clinical EA2 often fails to identify causative point
mutations. However, the last year has witnessed a further
step forward in understanding the genetic basis of EA2.
Veneziano and colleagues [28] identified new 5
0 and 3
0
regions in the CACNA1A gene, including a gene
promoter region and a new final exon 48, both of
which harboured mutations in patients with EA.
Furthermore, the mutations p e c t r u mh a se x p a n d e d
with the findings of large deletions and duplications in
CACNA1A in affected individuals. Previously, nonsense
and missense mutations accounted for most cases of
EA2. Recently, methods such as MLPA (multiplex
ligation-dependent probe amplification) and QMPSF
(quantitative multiplex polymerase chain reaction of
short fluorescent fragments) have demonstrated large-
scale CACNA1A gene rearrangements in patients with
EA2 [29,30]. This finding is particularly important for
those patients with clinical EA2 in whom sequencing of
CACNA1A fails to identify a point mutation.
EA2 is an autosomal dominant disease, and because
large deletions in CACNA1A are not likely to produce
functional transcripts, it is likely that reduced channel
density in the cerebellar circuit (possibly in Purkinje
cells, where these channels have been shown to play a
central role) is sufficient to cause episodes of ataxia.
Moreover, the recent observation that nonsense muta-
tions located within a well-known alternatively spliced
exon (exon 37A) [31] can cause EA2 hints at a significant
role of CaV2.1 channels containing exon 37A in the
cerebellum and underpins the importance of calcium
channel splicing in disease causation.
While increasing evidence points to a loss of robust CaV2.1
expression in the cerebellum and haploinsufficency as the
underlying mechanism of EA2, calcium channel
Figure 1. Two-dimensional schematic of the a-subunit of CaV2.1
showing functionally important regions of the peptide
The subunit consists of four domains (I-IV), each containing six
transmembrane segments (S1-S6). The S4 segment of each domain is lined
with positively charged amino acids and acts as the voltage sensor. The
S5-S6 interlinker forms the pore of the channel. The AID (alpha interaction
domain) forms the binding pocket for the b-subunit of CaV2.1. The
SYNPRINT (synaptic protein interaction) region interacts with SNARE
(SNAP (soluble N-ethylmaleimide-sensitive factor attachment protein)
receptor) proteins such as syntaxin and SNAP-25, which are involved in
synaptic transmission. Sites of G-protein modulation via bg-subunits are
shown along with the ‘EF’ hand, which is considered to be involved in
calcium-dependent facilitation.
Table 1. Mutations in CACNA1A underlie three allelic disorders: EA2, FHM and SCA6
Disease Core clinical features Additional features Inheritance Mutations Functional
consequences
Episodic ataxia type 2
(EA2)
Attacks of ataxia,
vomiting, vertigo,
oscillopsia lasting
hours to days, and
interictal nystagmus
Epilepsy, migraine, and
progressive cerebellar
syndrome
Autosomal dominant Nonsense and missense
mutations, small
deletions and insertions,
and large deletions
Loss of function
Familial hemiplegic
migraine type 1
(FHM1)
Rare subtype of MA:
attacks of hemiparesis
and hemisensory
disturbance lasting
hours to days
Confusion,
encephalopathy,
ataxia, coma,
and seizures
Autosomal dominant Missense mutations Gain of function
Spinocerebellar ataxia
type 6 (SCA6)
Late-onset progressive
cerebellar ataxia
Autosomal dominant CAG expansion in
C-terminus
Alteration of CaV2.1
channel kinetics; poly-
glutamine cytotoxicity?
The clinical and genetic features of each disorder are described. The effect of mutations on CaV2.1 channel function is stated. MA, migraine with aura.
Page 2 of 4
(page number not for citation purposes)
F1000 Biology Reports 2010, 2:4 http://F1000.com/Reports/B/2/4dysfunction may not be at the root of SCA6. In support of
this view, the expanded CAG repeat in the SCA6 knock-in
mouse does not appear to affect CaV2.1 function [32],
indicating that the polyglutamine repeat itself may have a
cytotoxic effect on the cell. It has recently been suggested
that cerebellar dysfunction in a related polyglutamine
repeat SCA (SCA2) may arise from aberrant activation of
type 1 inositol 1,4,5-trisphosphate receptors (ITPRs) in
Purkinje cells by the glutamine tracts themselves [33]. If
activation of the ITPRs is the mechanism of polyglutamine
repeat SCAs, then SCA6 may be a result of the relative
abundance of P/Q channels in Purkinje cells, rather than
specific properties of the channels themselves.
Future directions
Despite advances in the genetic basis of EA2, many
questions remain unanswered. From a mechanistic point
of view, the paroxysmal nature of the neurological sym-
ptoms arising from mutations in CACNA1A remains a
mystery. Inaddition, the physiological basis of howattacks
are precipitated by stress or indeed relieved by acetazola-
mide still evades explanation. Answers to some of these
questions may await the development of neuronal expres-
sion systems. This will allow the study of how genetic
variation in the calcium channel gene affects the biophy-
sical properties of CaV2.1 in its physiologicalenvironment,
especially with respect to synaptic transmission and
dendriticdepolarisation.Arecentinsightintothisapproach
came from Heeroma and colleagues [34], who demon-
strated that KV1.1 mutations in EA1 exerted differential
effects on excitation (rheobase) and synaptic transmission
when expressed in neurons.
Although the polyglutamine tract in SCA6 is considered
to confer a toxic gain of function, the exact roles of the
alternative long- and short-splice variants of CACNA1A in
Purkinje cells need to be defined. This may lead to a better
understanding of how the expanded CAG repeat in SCA6
results in disease. An additional conundrum is why many
spontaneous mutations in CACNA1A in mice result in a 3
Hz spike and wave epilepsy [35,36], whereas in humans,
althougha few mutationshavebeen showntoco-segregate
with EA2 and seizures [37,38], most deletions and trun-
cationsinthegeneareassociatedwithpureEA2ratherthan
absenceepilepsy.Mutationsofthisgeneappeartogivetwo
distinct phenotypes in humans and rodents. Understand-
inghowthesephenotypesareassociatedwithdifferentroles
of CaV2.1channelsinhumanandrodenttissuesmaybean
importantstepinuntanglingthemolecularpathogenesisof
seizures and ataxia.
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